Blueprint Medicines Corporation Overview
Pro stress-test →Blueprint Medicines is a Cambridge, Massachusetts-based biotechnology company focused on precision therapies for genomically defined cancers, certain blood disorders and immunology. The company's lead asset is Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent systemic mastocytosis, which generated $479M in revenue in 2024 and showed 60% year-over-year growth in Q1 2025.
Strategic Profile
Pro stress-test →Strong AYVAKIT demand and expanded market reach fuel revenue growth, while a diversified pipeline and efficient cost structure reduce reliance on a single product and support long-term earnings growth. Notably, Sanofi agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential contingent value rights payments worth up to $6 per share, bringing the total potential value to $9.5B.
Competitive Landscape
Pro stress-test →AYVAKIT is the only approved medicine for advanced and indolent systemic mastocytosis, providing a differentiated position in the rare disease immunology space. Competitors in adjacent rare disease and oncology segments include Gilead Sciences (focused on oncology and immunology) and Roche (broad therapeutic portfolio including targeted therapies). Blueprint's niche positioning in mast cell biology provides limited direct competition.
Industry Context
Blueprint Medicines Corporation operates in Biotechnology - Specialty Pharma & Rare Diseases.
Key facts
Founded: 2008 · Headquarters: Cambridge, US · Employees: N/A · Revenue: $0.56B (TTM as of April 2026) · Market cap: N/A